Frontiers in Endoscopy, Series #11Endoscopic Management of Pancreatic Duct Stones Via ERCP
Endoscopic sphincterotomy (ES) has allowed the development of interventional endoscopic procedures to remove pancreatic duct stones. These endoscopic approaches were less invasive than previously developed surgical measures to treat pancreatic duct stones and rapidly gained widespread acceptance. Other endoscopic procedures such as electrohydraulic lithotripsy, extracorporeal shock wave lithotripsy, and laser lithotripsy can be used in the removal of pancreatic duct stones. This manuscript will review the current state of the art with regards to endoscopic management of pancreatic duct stones.
Nutrition Issues in Gastroenterology, Series #130Nutrition Guidelines for Treatment of Children with Eosinophilic Esophagitis
Eosinophilic Esophagitis (EoE) is a chronic immune-/antigen-mediated disease characterized by clinical symptoms and histological changes induced by environmental and/or dietary triggers. Dietary intervention for EoE includes food eliminations, which can put patients at risk for poor nutrition intake. In this article, we discuss the integral role of a registered dietitian to assess growth, micronutrient intake and to provide guidance for implementing any elimination diet. Understanding typical presentations in patients with EoE help to determine nutrition risk, and target evaluation, education and regular follow-up are key.
Inflammatory Bowel Disease: A Practical Approach, Series #89Inflammatory Bowel Disease: The Bellevue Experience
The Bellevue IBD clinic serves a radically different patient population than is treated in most US healthcare settings, represented in most clinical trials, or reflected in current management guidelines. Here we discuss the complexity of providing care to these individuals, areas of disparity in IBD care and resources to assist our patient population
A Case ReportInfected Microabscesses In Congenital Hepatic Fibrosis and Subsequent Treatment With Liver Transplantation
FDA APPROVES TAKEDA'S ENTYVIO™ (VEDOLIZUMAB) FOR THE TREATMENT OF ADULTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS OR CROHN&rsquot;S DISEASE
Deerfield, Ill., and Osaka, Japan,- Takeda Pharmaceutical Company Limited ("Takeda") and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc., today announced that the United States (U.S.) Food and Drug Administration (FDA) simultaneously approved a new biologic therapy, Entyvio™ (vedolizumab), for the treatment of adults with moderately to severely active ulcerative colitis (UC) and Crohn’s disease (CD).